These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36467163)

  • 1. Qualified foreign institutional investors and corporate innovation: From the perspective of corporate governance.
    Wang X; Wang W; Shi XY
    Front Psychol; 2022; 13():1005409. PubMed ID: 36467163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institutional investors and cost of capital: The moderating effect of ownership structure.
    Huo X; Lin H; Meng Y; Woods P
    PLoS One; 2021; 16(4):e0249963. PubMed ID: 33831116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which institutional investors can improve the level of corporate ESG information disclosure?
    Wang J; Ke Y; Zhang H; Cheng Y
    PLoS One; 2023; 18(11):e0290008. PubMed ID: 37976317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of companies disclosing ESG reports in multiple languages on the enthusiasm of foreign investors for holding shares.
    Bao R; Wei L
    PLoS One; 2024; 19(3):e0299643. PubMed ID: 38452011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will R&D make investors more tolerant? Analysis based on the performance forecast of Chinese listed companies.
    Chen Y; Wang Y; Zhao H; Xu W
    PLoS One; 2023; 18(1):e0280237. PubMed ID: 36701361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can retail investors induce corporate green innovation? -Evidence from Baidu Search Index.
    Li M; Li N; Khan MA; Khaliq N; Rehman FU
    Heliyon; 2022 Jun; 8(6):e09663. PubMed ID: 35721685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indifferent to CSR performance? Market liberalization brings about changes.
    Zhou H; Xu L
    Heliyon; 2023 Nov; 9(11):e22172. PubMed ID: 38045161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does corporate governance affect financial analysts' stock recommendations, target prices accuracy and earnings forecast characteristics? An empirical investigation of US companies.
    Bouteska A; Mili M
    Empir Econ; 2022; 63(4):2125-2171. PubMed ID: 36118292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do Institutional Investors Influence Corporate Governance under Legal Psychology.
    Qi S
    J Environ Public Health; 2022; 2022():5004309. PubMed ID: 35978593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of executives' green experience on environmental, social, and governance (ESG) performance: Evidence from China.
    Chen C; Yan Y; Jia X; Wang T; Chai M
    J Environ Manage; 2024 Aug; 366():121819. PubMed ID: 39003908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. China's Insurance Regulatory Reform, Corporate Governance Behavior and Insurers' Governance Effectiveness.
    Li H; Zhang H; Tsai SB; Qiu A
    Int J Environ Res Public Health; 2017 Oct; 14(10):. PubMed ID: 29039781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea.
    Lee M
    Osong Public Health Res Perspect; 2015 Aug; 6(4):249-55. PubMed ID: 26473092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the Market Recognize the Value of the Corporate Governance Mechanism of Chinese Listed Companies?-Empirical Evidence From COVID-19.
    Li J; Ma Y; Shi B; Yang Y
    Front Public Health; 2021; 9():812253. PubMed ID: 35155358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of insurance institutional investors on corporate value from selection and creation perspective.
    Rong X; Zhang T; Liu K
    PLoS One; 2022; 17(7):e0269520. PubMed ID: 35776721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does CSR affect the cost of equity capital: Empirical evidence from the targeted poverty alleviation of listed companies in China.
    Yi Y; Xie B; Zhou L; Wei Y
    PLoS One; 2020; 15(2):e0227952. PubMed ID: 32032381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can fund shareholding inhibit insufficient R&D input?--Empirical evidence from Chinese listed companies.
    Li X; Liu G
    PLoS One; 2021; 16(3):e0248674. PubMed ID: 33765071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of China's ETS on Corporate Green Governance Based on the Perspective of Corporate ESG Performance.
    Yao R; Fei Y; Wang Z; Yao X; Yang S
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research on the Effect of Executive Incentive Institutional Innovation on the Cost of Equity-Evidence From Chinese Listed Companies.
    Wang J; Deng J
    Front Psychol; 2021; 12():686955. PubMed ID: 34168600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of enterprise financialization on green innovation: evidence from Chinese A-share non-financial listed enterprises.
    Li W; Chen L; He S
    Environ Sci Pollut Res Int; 2023 Apr; 30(19):56802-56817. PubMed ID: 36929262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.